Alkermes Plc Financial Overview

Author

Reads 8.2K

Brand Logo against Rainbow in White Background
Credit: pexels.com, Brand Logo against Rainbow in White Background

Alkermes Plc is a biopharmaceutical company with a market capitalization of $3.5 billion.

The company reported revenue of $1.3 billion in 2020, with a net loss of $1.1 billion.

Alkermes Plc has a significant presence in the US market, with a majority of its revenue coming from the sale of its products in the country.

The company's financial performance is heavily influenced by the sales of its lead product, Aristada, which generated $434 million in revenue in 2020.

You might enjoy: Alkermes Stock Quote

Financial Information

Alkermes plc has a total cash of $1.02 billion as of the most recent quarter. This is a significant amount of liquidity that can be used to fund operations, pay off debt, or make strategic investments.

Their debt-to-equity ratio is a relatively low 4.47%, indicating that the company has a manageable level of debt compared to its equity. This can be a positive sign for investors.

Here are some key financial metrics for Alkermes plc:

Their market capitalization is a substantial $4.70 billion, while their enterprise value is $3.75 billion.

Financial Highlights

Credit: youtube.com, Financial Statements Explained in One Minute: Balance Sheet, Income Statement, Cash Flow Statement

As we dive into the financial information, let's take a closer look at the company's financial highlights.

The company's total cash on hand is a substantial $1.02 billion, giving them a solid foundation for future investments and growth.

One key metric that stands out is the total debt to equity ratio, which currently sits at a relatively low 4.47%. This suggests that the company is not overly leveraged and has a healthy balance sheet.

Free cash flow is also a critical aspect of a company's financial health. In this case, the levered free cash flow over the trailing 12 months is a respectable $345.67 million.

Here's a quick snapshot of the company's financial highlights:

  • Total Cash (mrq): $1.02 billion
  • Total Debt/Equity (mrq): 4.47%
  • Levered Free Cash Flow (ttm): $345.67 million

Valuation Measures

Valuation Measures are an essential part of understanding a company's financial health. They provide a snapshot of a company's value and can help investors make informed decisions.

Market capitalization, or Market Cap, is a key valuation measure that indicates the total value of a company's outstanding shares. For the company in question, the Market Cap is a staggering 4.70 billion dollars.

Credit: youtube.com, "Master Financial Analysis: Stephen Penman's Guide to Security Valuation"

Enterprise Value, on the other hand, is a more comprehensive measure that takes into account both the company's debt and cash. The Enterprise Value for this company is 3.75 billion dollars.

The Price/Earnings Ratio, or P/E Ratio, is another important valuation measure that compares a company's stock price to its earnings per share. The Trailing P/E for this company is 13.74, indicating that investors are willing to pay 13.74 times the company's past earnings.

Looking ahead, the Forward P/E Ratio is 16.92, suggesting that investors expect the company's future earnings to grow.

The Price/Sales Ratio is 3.16, indicating that the company's stock price is 3.16 times its sales. This can be a useful metric for comparing companies in the same industry.

The Price/Book Ratio is 2.89, which means that the company's stock price is 2.89 times its book value. This can be a useful metric for investors who value companies with strong balance sheets.

Here are some key valuation measures for the company:

  • Market Cap: 4.70B
  • Enterprise Value: 3.75B
  • Trailing P/E: 13.74
  • Forward P/E: 16.92
  • Price/Sales (ttm): 3.16
  • Price/Book (mrq): 2.89
  • Enterprise Value/Revenue: 2.49
  • Enterprise Value/EBITDA: 8.34

Stock and Trading

Credit: youtube.com, 🔴 Alkermes Plc ALKS Stock Trading Facts 🔴

Alkermes plc is a publicly traded company with a ticker symbol of ALKS, listed on the NASDAQ exchange. This means you can easily buy or sell shares of the company through a brokerage account.

The company's fiscal year runs from January to December, which is a standard calendar year. This is important to keep in mind when reviewing the company's financial reports.

Alkermes plc's primary exchange is the NASDAQ, where you can find real-time quotes and other market data. If you're interested in trading the company's stock, this is the place to go.

The company's CIK Code is 0001520262, which is a unique identifier assigned by the Securities and Exchange Commission. This code can be useful when researching the company's filings and other public information.

Here are some key identifiers for Alkermes plc:

Management and Operations

At Alkermes plc, the management team is led by Chairman and Chief Executive Officer, Richard F. Pops. He oversees the company's overall strategy and direction.

Credit: youtube.com, Agiloft x Alkermes Customer Story

The company has a strong leadership team with several key executives holding important positions. Blair C. Jackson serves as Executive Vice President, Chief Risk Officer and Chief Operating Officer, while David Joseph Gaffin J.D. is Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary.

Here is a list of the key executives at Alkermes plc:

  • Richard F. Pops - Chairman and Chief Executive Officer
  • Blair C. Jackson - Executive Vice President, Chief Risk Officer and Chief Operating Officer
  • David Joseph Gaffin J.D. - Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
  • Dr. Craig C. Hopkinson M.D. - Executive Vice President of Research and Development and Chief Medical Officer
  • C. Todd Nichols - Senior Vice President and Chief Commercial Officer
  • Joshua Reed M.B.A. - Chief Financial Officer
  • Samuel J. Parisi - Interim Principal Accounting Officer and Vice President of Finance
  • Thomas Harvey - Chief Information Officer and Senior Vice President of IT
  • Sandra Coombs - Senior Vice President of Corporate Affairs and Investor Relations
  • Stephen Schiavo - Senior Vice President and Chief Human Resources Officer

Products

Alkermes has a diverse portfolio of proprietary commercial drug products.

The company's products include olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination. This combination is intended for the treatment of schizophrenia and bipolar I disorder.

Aripiprazole lauroxil (Aristada) is another notable product, a long-acting injectable for schizophrenia.

Naltrexone for extended-release injectable suspension (Vivitrol) is used for the treatment of alcohol and opioid dependence.

Other notable products utilizing Alkermes' proprietary technologies include diroximel fumarate (Vumerity) for multiple sclerosis, and risperidone (microspheres) long-acting injectable (Risperdal Consta) for schizophrenia and bipolar I disorder.

Credit: youtube.com, Operations Management FULL COURSE Introduction - A Complete Overview

Alkermes also developed paliperidone palmitate (Invega Sustenna, Invega Trinza and Invega Hafyerain in the U.S., Xeplion, Trevicta and Bynnali in Europe) for schizophrenia.

Here are some of Alkermes' notable products:

The company has also made progress in other areas, such as the initiation of a phase 2 study of alixorexton for the treatment of idiopathic hypersomnia.

Sales Forecasts

Alkermes Plc's sales are influenced by its drug revenue, which is forecasted to grow in the future.

The company's current and future drug revenue is a key factor in its sales forecasts, which are also influenced by consensus forecasts.

Alkermes Plc's sales are expected to be driven by its patient population, which is forecasted to grow over the next 8 years.

The company's market opportunity is closely tied to its patient population, which is a key factor in its sales forecasts.

Consensus forecasts suggest that Alkermes Plc's sales will be influenced by its ability to tap into its patient population, which is forecasted to grow significantly over the next 8 years.

Key Executives

Credit: youtube.com, General Manager, Operations Manager, & Top Executives Career Video

At the top of the company's management structure are the key executives, a team of highly skilled and experienced individuals responsible for making strategic decisions and overseeing daily operations.

Richard F. Pops serves as the Chairman and Chief Executive Officer, making him the highest-ranking executive in the organization.

Blair C. Jackson holds the position of Executive Vice President, Chief Risk Officer and Chief Operating Officer, indicating a strong focus on risk management and operational efficiency.

David Joseph Gaffin J.D. is the Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary, highlighting the importance of legal and compliance matters within the company.

Dr. Craig C. Hopkinson M.D. is the Executive Vice President of Research and Development and Chief Medical Officer, suggesting a strong emphasis on medical research and development.

The following table outlines the key executives and their roles:

Regulatory and Clinical

Alkermes plc has a strong focus on clinical trials, which is evident in their go-to-market proposition. They have a clear strategy in place for clinical operations, recruitment, and trial management.

Their clinical trials are a key part of their business, and they have a team in place to oversee the process.

Here's an interesting read: Best Place to Sell Crypto Wallet

Clinical Trials

Credit: youtube.com, What is Regulatory Affairs Management in Clinical Research?

Alkermes Plc's clinical operations are a crucial aspect of its business, and understanding its strategy can provide valuable insights. The company's clinical trials are a key part of its go-to-market proposition.

Determine Alkermes Plc's clinical operations by looking at its approach to recruitment and trial strategy. This information can help you understand the company's approach to bringing new treatments to market.

The company's clinical trials are focused on developing medicines for neurological conditions and cancer. These areas are a key focus for Alkermes Plc's R&D activities.

The company has a significant investment in its clinical operations, with a substantial R&D budget. In FY2024, the company spent US$239.6 million on its R&D activities, which as a percentage of revenue stood at 15.4%.

Alkermes Plc's R&D facility and corporate offices are located in Waltham, Massachusetts, the US, and the company also has an R&D and manufacturing facility in Athlone, Ireland.

Marketed Drugs

Alkermes plc has a diverse portfolio of marketed drugs, including ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia.

Credit: youtube.com, Regulatory and Clinical Trials for Therapeutics

Their product portfolio also includes ARISTADA INITIO for the treatment of schizophrenia in adults.

Another notable marketed drug is VIVITROL, used for the treatment of alcohol and prevention of opioid dependence.

LYBALVI, an oral atypical antipsychotic drug candidate, is being developed for the treatment of adults with schizophrenia and bipolar I disorder.

Alkermes plc's marketed drugs are designed to address unmet medical needs in various therapeutic areas.

Curious to learn more? Check out: Meyer Brothers Drug Company

Industry and Analyst

Alkermes plc has a strong presence in the industry, with a diverse portfolio of products that address unmet medical needs. The company's focus on central nervous system (CNS) disorders has led to the development of innovative treatments.

Alkermes has received recognition from industry analysts, with a rating of "outperform" from 75% of analysts surveyed. This confidence in the company's prospects is reflected in its market value, which has consistently increased over the years.

The company's commitment to research and development is evident in its investment in new technologies, including its proprietary ALKS 3831 product.

Catalyst Calendar

Credit: youtube.com, Biopharma Stock Investing | Catalyst Events Explained

Staying ahead of the competition requires being proactive in evaluating catalyst impacts for companies like Alkermes Plc. This helps improve corporate planning and bolsters business development with timely opportunities.

Alkermes Plc's product portfolio can shift rapidly, making it essential to identify which products will be commercialized. This allows you to stay one step ahead of the market.

By evaluating catalyst impacts, you can better contend with shifting product portfolios, giving you a competitive edge in the industry.

A fresh viewpoint: General Catalyst

Drug Manufacturers: Specialty & Generic

Alkermes plc is a biopharmaceutical company that researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the United States, Ireland, and internationally.

Founded in 1987, Alkermes plc is headquartered in Dublin, Ireland. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder.

Alkermes plc's marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia, and VIVITROL for the treatment of alcohol and prevention of opioid dependence.

The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.

Additional reading: Bringing Alcohol

Analyst Recommendations

Credit: youtube.com, I followed analyst recommendations for a year. Here's what happened.

Analyst Recommendations are crucial in helping investors make informed decisions about stocks to buy or sell.

Analysts from top firms like Goldman Sachs and Morgan Stanley have given positive ratings to companies like Amazon and Microsoft.

A strong recommendation from a reputable analyst can significantly boost a company's stock price.

According to analyst estimates, Amazon's stock is expected to grow by 20% in the next quarter.

Analysts also look at a company's financial health, such as its revenue and profit margins, when making recommendations.

Companies with strong financials, like Apple, often receive high ratings from analysts.

Analyst recommendations can be a valuable tool for investors, but it's essential to do your own research and consider multiple sources before making a decision.

Frequently Asked Questions

What drugs are made by Alkermes?

Alkermes develops medications such as Lybalvi (olanzapine and samidorphan) and Aristada (aripiprazole lauroxil). Their portfolio also includes naltrexone for extended-release injectable suspension.

Lee Kuhn

Senior Copy Editor

Lee Kuhn has spent over two decades refining his craft as a copy editor, honing a keen eye for detail and a passion for precise language. His expertise extends to a variety of fields, with a particular focus on the intricate world of Finnish banking. Lee's rigorous approach to editing ensures that every piece he touches is not only free of errors but also clear and compelling.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.